Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens

An Open-Label, Single-Dose, Non-Randomized, 4-Period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00550303

Enrollment

Registered

2007-10-29

Start date

2007-10-31

Completion date

2007-11-30

Last updated

2007-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen formulations for future testing purposes.

Interventions

DRUGbazedoxifene/conjugated estrogens combination

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

45 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy, post menopausal women ages 45 to 70

Exclusion criteria

* Male subjects

Design outcomes

Primary

Measure	Time frame
Bioavailability	—

Secondary

Measure	Time frame
Safety & tolerability	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026